Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial

Salim S. Virani, Julia M. Akeroyd, Vijay Nambi, Erin D. Michos, Pamela B. Morris, Khurram Nasir, Sidney C. Smith, Neil J Stone, Laura A. Petersen, Christie M. Ballantyne

Research output: Contribution to journal › Letter

LanguageEnglish (US)
Pages410-412
Number of pages3
JournalCirculation
Volume139
Issue number3
DOIs
StatePublished - Jan 15 2019

Fingerprint

Cholesterol
Clinical Trials
Costs and Cost Analysis
Proprotein Convertase 9

Keywords

  • cholesterol
  • clinical trial

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Virani, S. S., Akeroyd, J. M., Nambi, V., Michos, E. D., Morris, P. B., Nasir, K., ... Ballantyne, C. M. (2019). Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation, 139(3), 410-412. https://doi.org/10.1161/CIRCULATIONAHA.118.034993
Virani, Salim S. ; Akeroyd, Julia M. ; Nambi, Vijay ; Michos, Erin D. ; Morris, Pamela B. ; Nasir, Khurram ; Smith, Sidney C. ; Stone, Neil J ; Petersen, Laura A. ; Ballantyne, Christie M. / Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. In: Circulation. 2019 ; Vol. 139, No. 3. pp. 410-412.
@article{ece5249b61f646eb8b722bdbf701883a,
title = "Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial",
keywords = "cholesterol, clinical trial",
author = "Virani, {Salim S.} and Akeroyd, {Julia M.} and Vijay Nambi and Michos, {Erin D.} and Morris, {Pamela B.} and Khurram Nasir and Smith, {Sidney C.} and Stone, {Neil J} and Petersen, {Laura A.} and Ballantyne, {Christie M.}",
year = "2019",
month = "1",
day = "15",
doi = "10.1161/CIRCULATIONAHA.118.034993",
language = "English (US)",
volume = "139",
pages = "410--412",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Virani, SS, Akeroyd, JM, Nambi, V, Michos, ED, Morris, PB, Nasir, K, Smith, SC, Stone, NJ, Petersen, LA & Ballantyne, CM 2019, 'Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial', Circulation, vol. 139, no. 3, pp. 410-412. https://doi.org/10.1161/CIRCULATIONAHA.118.034993

Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. / Virani, Salim S.; Akeroyd, Julia M.; Nambi, Vijay; Michos, Erin D.; Morris, Pamela B.; Nasir, Khurram; Smith, Sidney C.; Stone, Neil J; Petersen, Laura A.; Ballantyne, Christie M.

In: Circulation, Vol. 139, No. 3, 15.01.2019, p. 410-412.

Research output: Contribution to journal › Letter

TY - JOUR

T1 - Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial

AU - Virani, Salim S.

AU - Akeroyd, Julia M.

AU - Nambi, Vijay

AU - Michos, Erin D.

AU - Morris, Pamela B.

AU - Nasir, Khurram

AU - Smith, Sidney C.

AU - Stone, Neil J

AU - Petersen, Laura A.

AU - Ballantyne, Christie M.

PY - 2019/1/15

Y1 - 2019/1/15

KW - cholesterol

KW - clinical trial

UR - http://www.scopus.com/inward/record.url?scp=85060035929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060035929&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.118.034993

DO - 10.1161/CIRCULATIONAHA.118.034993

M3 - Letter

VL - 139

SP - 410

EP - 412

JO - Circulation

T2 - Circulation

JF - Circulation

SN - 0009-7322

IS - 3

ER -

Virani SS, Akeroyd JM, Nambi V, Michos ED, Morris PB, Nasir K et al. Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 Jan 15;139(3):410-412. https://doi.org/10.1161/CIRCULATIONAHA.118.034993

Access to Document